Global HutchinsonGilford Progeria Syndrome HGPS Share Analysis 2025, Forecast To 2034
26 Mar, 2025
What Has Been The Evolution of the HutchinsonGilford Progeria Syndrome HGPS Market in Recent Years?
The hutchinsongilford progeria syndrome hgps market has seen considerable growth due to a variety of factors.
• The market size of Hutchinson-Gilford Progeria Syndrome (HGPS) has seen a substantial increase in recent years. The market is projected to expand from $97.63 billion in 2024 to $106.56 billion in 2025, with a compound annual growth rate (CAGR) of 9.1%.
The growth seen in the historic period can be linked to an increase in awareness about rare genetic disorders, a rise in funding for progeria research, the widening of genetic testing, the introduction of government initiatives for rare diseases, and an increase in the global presence of genetic disorders.
How Will the HutchinsonGilford Progeria Syndrome HGPS Market?
The hutchinsongilford progeria syndrome hgps market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for significant expansion within the hutchinson-gilford progeria syndrome (HGPS) market in the coming years. The market is projected to increase in value to $149.22 billion by the time 2029 arrives, with a compound annual growth rate (CAGR) of 8.8%.
The upcoming growth could largely be attributed to factors such as: an increase in funds for research and development of new treatments, a growing occurrence of progeria, an upsurge in global health expenditure, a higher propensity for adopting new therapeutic methods, along with a mounting demand for prior diagnosis. The period of forecast also anticipates major trends which include: technological progression, the creation of focused treatments, advancements in the technology of next-generation sequencing (NGS), the development of biomarkers and the progression of drug delivery systems.
Which Factors Are Boosting Growth In The HutchinsonGilford Progeria Syndrome HGPS Market?
The amplified investment towards research and development dedicated to the discovery of new treatments is projected to boost the expansion of the hutchinson-gilford progeria syndrome (HGPS) market. The term 'Funding for Research and Development' relates to monetary resources designated for fostering innovation, raising scientific knowledge, and creating technological resolutions. This surge in funding is associated with elements like growing demand for creative treatments and government assistance for healthcare progress. Enhanced research and development funding speeds up the progress of hutchinson-gilford progeria syndrome treatments, supporting clinical testing and nurturing groundbreaking therapies. It encourages the comprehension of the genetic roots of this condition, thus assisting in formulating targeted solutions. For example, data from the Office for National Statistics, a government agency based in the UK, reveals that in 2022, the net expenditure on research and development (R&D) by the UK government escalated by 10.5%, climbing to £15.5 billion ($17.59) from £14.0 billion ($15.88) in 2021. Thus, the heightened funding for the research and development of new treatments propels the growth of the hutchinson-gilford progeria syndrome (HGPS) market.
What Key Areas Define The Segmentation Of The Global HutchinsonGilford Progeria Syndrome HGPS Market?
The hutchinson-gilford progeria syndrome (HGPS) market covered in this report is segmented –
1) By Treatment Type: Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)), Low-dose Aspirin, Physical And Occupational Therapy, Hearing Aids, Genetic Counseling, Other Treatment Types
2) By Route Of Administration: Oral, Injectable, Intravenous, Transdermal
3) By Mechanism Of Action: Antisense Oligonucleotides, Crispr-cas9 Gene Editing, Rna Interference, Targeted Drug Delivery Systems
4) By End-User: Hospitals, Specialty Clinics, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Farnesyltransferase Inhibitors (Zokinvy (Lonafarnib)): Monotherapy With Lonafarnib, Combination Therapy With Other Drugs
2) By Low-dose Aspirin: Cardiovascular Protection, Anti-inflammatory Therapy
3) By Physical And Occupational Therapy: Mobility Support And Rehabilitation, Joint And Bone Health Management, Adaptive Equipment For Daily Activities
4) By Hearing Aids: Conventional Hearing Aids, Bone-Anchored Hearing Aids (BAHA), Cochlear Implants
5) By Genetic Counseling: Family Genetic Testing, Genetic Risk Assessment, Prenatal Counseling And Guidance
6) By Other Treatment Types: Stem Cell Therapy, Gene Editing and Therapy, Nutritional Support And Management
What Trends Are Reshaping The Future Of The HutchinsonGilford Progeria Syndrome HGPS Market?
Key players in the hutchinson-gilford progeria syndrome (HGPS) market are concentrating their efforts on creating improved farnesyltransferase inhibitors to enhance the efficiency of treatments and decelerate disease progression in patients. Farnesyltransferase inhibitors are drugs designed to obstruct farnesyltransferase, an enzyme that contributes to protein changes, thereby curbing irregular cell expansion and aging. For instance, Eiger BioPharmaceuticals, a biopharmaceutical enterprise based in the US, got marketing approval from the European Commission in July 2022 for Zokinvy. Not only is it the first and sole treatment approved in Europe for hutchinson-gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL) for children and young adults, but it is also a disease-modifying agent taken orally. Clinical trials showed that Zokinvy reduced the mortality rate in children by 72% and increased life expectancy by approximately 4.3 years on average. The marketing authorization given by the European Commission is applicable in all 27 EU countries, as well as Iceland, Liechtenstein, and Norway.
Who Are the Key Players In The HutchinsonGilford Progeria Syndrome HGPS Market?
Major companies operating in the hutchinson-gilford progeria syndrome (HGPS) market are:
• National Institutes of Health (NIH)
• Mount Sinai
• Johns Hopkins Hospital
• Duke University
• Mayo Foundation for Medical Education and Research
• Cleveland Clinic
• Children's Hospital of Philadelphia
• St. Jude Children's Research Hospital
• Cincinnati Children's Hospital Medical Center
• University of Maryland
• Boston Children's Hospital
• Children’s Hospital Los Angeles
• Harvard Medical School
• The Scripps Research Institute
• Blueprint Genetics
• Medicover Hospitals
• Sentynl Therapeutics
• UCSF Helen Diller Family Comprehensive Cancer Center
• Progeria Research Foundation
• AnGes MG Inc.
• PRG Science & Technology Co. Ltd.
What Is The Most Dominant Region In The HutchinsonGilford Progeria Syndrome HGPS Market?
North America was the largest region in the hutchinson-gilford progeria syndrome (HGPS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hutchinson-gilford progeria syndrome (HGPS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.